Are you Dr. Sadeh?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
500 W 43rd St
Apt. 15b
New York, NY 10036Phone+1 212-594-6340
Summary
- Dr. Jonathan Sadeh, MD is an emergency medicine physician in New York, New York. He is currently licensed to practice medicine in New York and Massachusetts.
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2004
Boston University Medical CenterResidency, Internal Medicine, 1996 - 1999
Icahn School of Medicine at Mount SinaiClass of 1996
Certifications & Licensure
NY State Medical License 2005 - 2026
MA State Medical License 1998 - 2011
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2013
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2013
Publications & Presentations
PubMed
- 10 citationsWhere are the new cough treatments: a debriefing of recent clinical proof-of-concept trials with the NOP agonist SCH 486757.Robbie L. McLeod, Deen Tulshian, Jonathan S. Sadeh
Pharmacology. 2011-07-15 - 9 citationsCysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma.Shamsah Kazani, Jonathan Sadeh, Sreedhar Bunga, Michael E. Wechsler, Elliot Israel
Respiratory Medicine. 2011-05-01 - 32 citationsThe Efficacy of a NOP1 Agonist (SCH486757) in Subacute CoughAshley Woodcock, Robbie L. McLeod, Jonathan S. Sadeh, Jaclyn A. Smith
Lung. 2010-01-01
Press Mentions
New Zeposia (Ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple SclerosisOctober 26th, 2022- New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (Ozanimod) Treatment Prevents Disease Relapse over One Year in 86.1% of Patients Who Respond at the End of the Induction PeriodOctober 24th, 2022
- FDA Approves Drug Sotyktu for Treatment of Plaque PsoriasisSeptember 10th, 2022
- Join now to see all
